Get started
Insmed IncorporatedInsmed IncorporatedInsmed Incorporated

Insmed Incorporated

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

INSM trade ideas

Insmed Catapults 113% on Positive ASPEN Study ResultsInsmed ( NASDAQ:INSM ), a biotech company, has successfully developed a lung disease drug, brensocatib, which has been shown to significantly reduce the frequency of respiratory symptoms such as chronic cough in a late-stage study. The drug, which is expected to be launched in mid-2025, is expected to be approved by the FDA in the fourth quarter of this year. The company also plans to launch the drug in Europe and Japan in the first half of 2026. Bronchiectasis is a chronic lung disease that affects 350,000 to 500,000 adults in the United States and has no approved treatments currently. The results validate Insmed's theory that blocking an enzyme called DPP1 can help treat some inflammatory diseases. The market potential for brensocatib is "very attractive," with the potential to expand several-fold with a simple CT scan, potentially identifying more NCFB patients who are currently diagnosed with COPD (chronic obstructive pulmonary disease). Insmed ( NASDAQ:INSM ) tested two doses of brensocatib, with the low dose leading to a 21.1% reduction in the number of lung exacerbations a patient would be expected to experience in a year, while the high dose led to a 19.4% reduction in the annualized rate of pulmonary exacerbations. The results were encouraging, but questions remain about whether patients received Arcturus' drug on top of Vertex Pharmaceuticals' Trikafta, a standard treatment for cystic fibrosis. Insmed ( NASDAQ:INSM ) stock has skyrocketed 112.9% to 46.84 in morning trades on the stock market. The low dose led to a 21.1% reduction in the number of lung exacerbations a patient would be expected to experience in a year, while the high dose resulted in a 19.4% reduction in the annualized rate of pulmonary exacerbations. In related news, Arcturus Therapeutics (ARCT) stock soared 23.1% to 37.42 on a positive update for its cystic fibrosis treatment. Patients with cystic fibrosis have mutations in their CFTR gene, and Arcturus uses an inhaled drug to deliver messenger RNA to patients' lungs. Four patients received two doses of Arcturus' drug over eight days, and on average, they had a 4% improvement in how much air they could expel for one second, a key test of lung function in cystic fibrosis. Insmed stock ( NASDAQ:INSM ) has outperformed lately and has bounded off its 50-day Moving Average (MA) on the news. The stock is currently overbought trading with a Relative Strength Index (RSI) of 83.47.
NASDAQ:INSMLong
by DEXWireNews
Insmed Incorporated (INSM: NASDAQ)Insmed Incorporated (INSM), a biopharmaceutical company, is showing positive developments in its product portfolio. The company reiterated its 2023 guidance, expecting revenue between $295-305 million, with strategic plans to expand the use of its ARIKAYCE product. Encouraging Phase 2 data for its TPIP drug, used in pulmonary hypertension treatment, highlights its commitment to developing effective therapies. Investors are eagerly awaiting the Phase 3 ASPEN Trial results for Brensocatib in Q2 2024, which could significantly boost the company's growth. Market sentiment is bullish on INSM, particularly if the stock stays above the $22.50-$23.00 range, with an upside target set between $32.00 and $33.00.
NASDAQ:INSMLong
by Richtv_official
Big Potential For INSMED Daily Hey guys, INSMED is in a bullish push with high volume buy executed and a water-carrying candle shape followed by short legs. The TIMEFRAME M1 shows us a kind of hammer candle with a high negotiated sales volume, it wanted to bounce back from the bollinger base. But it was a failure passing on its low point to come back to test the base and the top of the equilibrium zone. High probability of breaking the price with momentum then then the zone to interfere with the other and land on the high which follows. With the filling of a gap of the bearish break before going to the lower unit we see an adjustment (for the TIMEFRAME H4). And on (the TIMEFRAME H1) the same then an excess before breakout of a zone of balance. Not enough buying force to test half of ANDREWS PITCHFORK's intermediate median. Please LIKE & FOLLOW, thank you!
NASDAQ:INSMShort
by stephanelibatd